Betta Pharmaceuticals shareholder increases pledged holdings

Betta Pharmaceuticals announced today that its shareholder, Ningbo Kaiming Investment Management Partnership (Limited Partnership) (Kaiming Investment), has increased its pledged holdings. Kaiming Investment newly pledged 9,349,400 shares, representing 11.68% of its total holdings and 2.22% of the company's total share capital. The pledge, for self-operation purposes, commenced on December 22, 2025, and is set to mature on December 31, 2027, with China Minsheng Trust Co., Ltd. as the pledgee.

Following this transaction, Kaiming Investment and its concerted parties, Zhejiang Beicheng Investment Management Partnership (Limited Partnership) (Beicheng Investment) and Ding Lieming, have a cumulative 61,130,804 shares pledged, which constitutes 67.17% of their total holdings. The company's controlling shareholders and concerted parties have approximately 22,265,551 shares maturing within the next six months, representing 24.46% of their holdings and 5.29% of the company’s total share capital, corresponding to a financing balance of 41,150,000 yuan. An additional 14,600,500 shares will mature within the next year, with a financing balance of 28,250,000 yuan.

The company stated that this pledge does not involve financing for operational needs and that Kaiming Investment has sufficient funds for repayment. The pledge is not expected to impact Betta Pharmaceuticals’ operations, governance, or financial condition, and there is no current risk of forced liquidation or changes in control.